By Dr Laura Figulla (mbiomics)2024-04-30T12:22:00
Dr Laura Figulla is the CEO of mbiomics. Laura co-founded mbiomics which is dedicated to unlocking the true value of the microbiome by developing next-generation live biotherapeutics (LBPs). Throughout her career, Laura has combined her entrepreneurial spirit with her diverse academic background in business, economics, and medicine to build companies ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2023-06-29T09:19:53
Sponsored by BMG Labtech GmbH
2024-02-07T14:34:33
Sponsored by BellBrook Labs
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2023-07-04T10:05:58
Sponsored by Revvity
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
Site powered by Webvision Cloud